THE TSWAKA STUDY the Tswaka Stdy a Journey Into an Innovatve Public–Private–Private Researc Partnersip

Total Page:16

File Type:pdf, Size:1020Kb

THE TSWAKA STUDY the Tswaka Stdy a Journey Into an Innovatve Public–Private–Private Researc Partnersip newsnews24 THE TSWAKA STUDY The Tswaka Stdy A journey into an innovatve public–private–private researc partnersip Saskia JM Osendarp, Dominic Schofeld Global Alliance for Improved Nutrition (GAIN), > This report summarizes the key lessons learned and Geneva, Switzerland discusses what it takes to make such partnerships work. The key lessons appear on pp. 28–29. Maaike J Bruins DSM Nutritional Products, Basel, Switzerland This is a report on the learnings gathered by a unique partner- Leon GJ Frenken ship, consisting of two private-sector partners, one NGO and an Unilever R&D, Vlaardingen, the Netherlands academic partner, established to perform a complex study: the Tswaka Nutrition Intervention study. Jane Badham The study was a community-based randomized controlled JB Consultancy, Johannesburg, South Afica trial carried out in North West province, South Afica, on the efcacy of two small-quantity lipid-based complementary food Klaus Kraemer supplements provided to children aged 6–12 months. The Tswa- Sight and Life Foundation, Basel, Switzerland ka study – which means ‘mixing’ in the local Setswana language, referring to the fact that the supplement should be mixed into Cornelius M Smuts home-cooked food – was completed in 2015, and its results have Centre of Excellence for Nutrition, recently been published.1 North-West University, Potchefstroom, South Afica The journey embarked on in 2010 presented many challeng- es before it was successflly completed following eight years of efort. This report summarizes the key lessons learned and dis- Key messages cusses what it takes to make such partnerships work. We hope that our experiences and insights will be of value to others en- > This is a report on the learnings gathered by a partnership tering into partnerships in the nutrition space. In the end, our established to perform a complex study: the Tswaka Nutri- joint success came down to the three Ps: Personal relationships tion Intervention study. and trust, Perseverance and determination, and the Passion to make this project a success. > The study was a community-based randomized controlled trial carried out in North West province, South Africa, on the Inception: aligning motivations efcacy of two small-quantity lipid-based complementary to create a single concept food supplements provided to children aged 6–12 months. In 2010, an NGO (GAIN) and a private-sector partner (Unilever) joined forces as a Funding Consortium to facilitate a research > The Tswaka study was completed in 2015 and its results project investigating a novel fortifed complementary food sup- have been recently published.1 plement. For the detailed design and execution of the interven- tion study, it was decided that an Academic Research Partner would be selected via a call for proposals. SIGHT AND LIFE | VOL. 33(1) | 2019 25 Saskia Osendarp © One of the children participating in the Tswaka Study has her weight taken as part of the bimonthly anthropometric measurement process 26 THE TSWAKA STUDY The motivation for the study was diferent for each of the research team. Therefore, two contracts had to be aligned and partners in the Funding Consortium. While GAIN was interested agreed upon: one bilateral grant agreement between GAIN and in working with private-sector partners on product formulation the research team, and one trilateral agreement between GAIN and demonstration of the feasibility of a market-based approach, and the two private-sector partners (the Funding Consortium), Unilever was interested in testing the efcacy of such a product who each contributed one-third of the research costs. before considering an innovation project on the feasibility of a Issues concerning intellectual property (IP) rights for data market-based approach. and for products, as well as publication and dissemination Unilever wanted to collaborate with GAIN on this research clearance procedures, had to be discussed at senior manage- because GAIN was considered a trusted intermediary between ment level in all the partner organizations. The entire contract Unilever and the Academic Research Partner. Initial discussions negotiations took more than a year and were eventually con- between Unilever and GAIN, however, identifed a potential con- cluded in 2011. fict of interest if GAIN were to work on a study assessing the efcacy of a product fom just one private-sector partner. Preparation phase: managing risks and building trust To address this issue, a second private partner, DSM, was The preparation phase turned out to be the most delicate phase invited to join the partnership. DSM wished to demonstrate ef- of the entire process. There were no products ready yet, and fcacy for a similar product formulation that contained certain negotiations started between the two private-sector partners extra ingredients with additional benefts for growth and devel- with the aim of creating a single joint development process for opment. Despite their diferent motivations, the three partners the study products. A joint development process was thought to recognized the benefts of sharing their complementary exper- be benefcial because this would allow for blinding of the two tise as well as sharing the research costs within the famework intervention arms by having two products comparable in taste of an NGO/private-partner Funding Consortium. and appearance, albeit with diferent compositions. As product To align the diferent motivations into one achievable goal development and product ingredient formulations are among a acceptable to all three partners took some time. There were company’s most valued IP, it took some time for the two pri- discussions about the requisite levels of transparency and vate partners to agree on a joint development agreement (JDA). openness and about the dynamics driving the choices and de- When an issue occurred during the actual production of one of cisions required for a successfl partnership. To avoid potential the study products, however, the private-sector partners decid- complications and to keep the study to a manageable size and ed to terminate the JDA and to continue frther scale-up and acceptable cost levels, it was designed in such a way that the production independently of one another. sample size would not allow direct comparison between the two In March 2013, the acceptability study among mothers and products. children with the frst product samples started in South Afica. The acceptability study yielded positive results but also revealed “ The more organizatons you have to some mild side efects, assessed as being unrelated to the in- tervention products as such.3 Meanwhile, however, within the involve, the more important it is to private-sector partners, changes in leadership and company have regular, open communicaton”2 strategies had taken place, leading to a revised assessment of the potential reputational risk for all partners involved in this community-based trial among very young and vulnerable chil- While these initial discussions were still ongoing, and prior dren in a disadvantaged population. to DSM joining the partnership, GAIN and Unilever had already To better manage and control these risks, it was initially developed a call for proposals based on an initial concept note, decided to hire an independent monitor to remotely review and an independent expert committee was formed to select the the quality of the study execution. In addition, a Safety Moni- Academic Research Partner to perform the study. toring Board (SMB) was established to monitor adverse efects North-West University, South Afica, won the bid in partner- and identif any potential causal relationships to study par- ship with the South Afican Medical Research Council (‘the re- ticipation or test product. In addition, an independent study search team’) and started to work on a fll proposal, which had physician was hired to train and support the research team as to be adapted into a three-arm design when the second private and when needed. The study monitoring was frther upscaled partner, DSM, joined the Funding Consortium. by hiring an independent Contract Research Organization Simultaneously, contract negotiations had started. The idea (CRO) to ensure the quality and safety of the study by mon- was that GAIN would act as the ofcial study sponsor, and also itoring the implementation of the study on site and for data as an intermediary between the private-sector sponsors and the management on site. SIGHT AND LIFE | VOL. 33(1) | 2019 THE TSWAKA STUDY 27 There was a clear need to balance the risk exposure of all made in keeping the momentum fom the site visit with the parties involved. Whereas the private partners wished to imple- community and the feld workers. To keep the onsite research ment processes such as monitoring, a centralized database and team motivated, extra training opportunities were ofered by extensive medical supervision and reporting, the research team the fnding partners. wished to make sure that its credibility as an independent aca- demic team would not be jeopardized. “ The fac that there was a signed Having an intermediate party in the form of GAIN turned out to be critical, ensuring efective communication between the obligaton beteen the partners research team and the private-sector partners and coordinat- meant we had to move forward and ing negotiations about the changing needs of both the research team and the Funding Consortium. could not withdraw” In addition, a site visit by the Funding Consortium helped to provide a more realistic view of the circumstances at the study site and to improve understanding of the practical dilemmas The renewed confdence within the partnership allowed for the research team faced in day-to-day management of a com- more open discussions on the issues of sponsor involvement munity-driven study of this size in this setting. It also frther and authorship. The dilemma was whether the growing in- strengthened trust between the responsible individuals within volvement of the study sponsors in the various stages of study each of the partner organizations.
Recommended publications
  • DSM's Integrated Annual Report 2015
    Royal DSM Integrated Annual Report 2015 WorldReginfo - c41a4efa-17eb-497c-8f68-03022dabfb88 WorldReginfo - c41a4efa-17eb-497c-8f68-03022dabfb88 DSM at a glance Nutrition DSM Resins & Functional Materials is a global player in developing, manufacturing and marketing high-quality resins The Nutrition cluster comprises DSM Nutritional Products and solutions for paints, industrial coatings and fiber-optic coatings. DSM Food Specialties.These businesses serve the global Continuous innovation means that customers can meet industries for animal feed, food and beverage, pharmaceutical, regulatory needs and respond better to consumer demands for infant nutrition, dietary supplements and personal care. more sustainable materials. DSM Nutritional Products is one of the world’s leading Innovation Center producers of essential nutrients such as vitamins, carotenoids, nutritional lipids and other ingredients to the feed, food, DSM Innovation Center serves as an enabler and accelerator pharmaceutical and personal care industries. Among its of innovation within DSM as well as providing support to the customers are the world’s largest food and beverage clusters. With its Emerging Business Areas, the Business companies. DSM is uniquely positioned thanks to the Incubator and DSM Venturing & Licensing, the DSM Innovation combination of its broad portfolio of active ingredients, maximum Center has a general business development role, focusing on differentiation through formulation, local presence, a global areas outside the current scope of the business groups. premix network, and a strong focus on innovation. DSM Nutritional Products consists of the following business units: DSM’s Emerging Business Areas provide strong long-term growth platforms based on the company’s core competences Animal Nutrition & Health addresses the nutritional additives in life sciences and materials sciences.
    [Show full text]
  • Royal DSM N.V. Annual Report 2006
    Royal DSM N.V. Annual Report 2006 Brighter Wider Better Together DSM Profile DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM’s products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM’s strategy, named Vision 2010 – Building on Strengths, focuses on accelerating profitable and innovative growth of the company’s specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. Annual Report 2005 www.dsm.com DSM at a glance DSM’s activities have been grouped into business groups representing coherent product / market combinations. The business group directors report directly to the Managing Board. Nutrition Pharma €2,407m €916m DSM Nutritional Products DSM Pharmaceutical Products DSM Nutritional Products is the world’s largest supplier of nutri- DSM Pharmaceutical Products is one of the world’s leading tional ingredients, such as vitamins, carotenoids (anti-oxidants providers of high quality global custom manufacturing services and pigments), other biochemicals and fine chemicals, and to the pharmaceutical, biotech and agrochemical industries.
    [Show full text]
  • Integrated Reporting As a Driver for Integrated Thinking?
    Integrated Reporting as a driver for Integrated Thinking? Maturity of <IR> in the Netherlands 2015 Contributors Patrick Seinstra Jennifer Muller Royal BAM Group: Barry Oesman Partner Integrated & Sustainability Deloitte Audit Master Student at London School of Economics and Group Controller Political Science Anneke Sipkens DSM: Kimberley Chan Director Sustainability Deloitte Risk Services Michiel van der Valk Sustainability Manager Master Student Sustainable Business & Innovation at Udeke Huiskamp Utrecht University Nutreco: Jose Villalon Senior Manager Sustainability Deloitte Risk Services Corporate Sustainability Director CSR the Netherlands (MVO Nederland) Erica Kostense-Smit Willem Lageweg Nutreco: Sigrid van Amerongen Manager Sustainability Deloitte Risk Services CEO CSR The Netherlands (MVO Nederland) CSR Manager Ashley Myers Vincent van Marle Heineken International: Jan-Willem Vosmeer Manager Sustainability Deloitte Risk Services Manager CSR Manager Frank Geelen Interviewees Delta Lloyd: David Hoppe Partner CFO Services & Finance Transformation NS: Carola Wijdoogen Communications Advisor Deloitte Consulting Director Sustainable Business Ministry of Economic Affairs: Martin Lok Marco van der Vegte KPN: Hans Koeleman Program Manager Natural Capital Managing Partner Audit and Member Executive Board Director Corporate Communications & CSR Deloitte Holding Avans Hogeschool: Marleen Janssen Groesbeek KPN: Brechtje Spoorenberg Professor Sustainable Finance and Accounting Olivier van Thuijl Manager CSR Senior Manager CFO Services Deloitte
    [Show full text]
  • THERMO FISHER SCIENTIFIC INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2018 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 1-8002 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 04-2209186 (State of incorporation or organization) (I.R.S. Employer Identification No.) 168 Third Avenue Waltham, Massachusetts 02451 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (781) 622-1000 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Name of each exchange on which Title of each class registered Title of each class registered Common Stock, $1.00 par value New York Stock Exchange 2.000% Notes due 2025 New York Stock Exchange Floating Rate Notes due 2019 New York Stock Exchange 1.400% Notes due 2026 New York Stock Exchange Floating Rate Notes due 2020 New York Stock Exchange 1.450% Notes due 2027 New York Stock Exchange 1.500% Notes due 2020 New York Stock Exchange 1.375% Notes due 2028 New York Stock Exchange 2.150% Notes due 2022 New York Stock Exchange 1.950% Notes due 2029 New York Stock Exchange 0.750% Notes due 2024 New York Stock Exchange 2.875% Notes due 2037 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Aegon N.V. Executive Board Remuneration Policy 2020
    Aegon N.V. Executive Board Remuneration Policy 2020 The Hague, March 2020 Executive Board Remuneration Policy 2020 Version History Last Version March 24, 2011 Revised and updated March 11, 2020 Endorsed by the Supervisory Board of Aegon N.V. March 17, 2020 Adopted by Shareholders at the Annual General Meeting of Shareholders May 15, 2020 2 Executive Board Remuneration Policy 2020 1. Policy 1.1 Remuneration Policy This Executive Board Remuneration Policy (the 'Policy') outlines the terms and conditions for the board agreement with and remuneration of the members of the Executive Board of Aegon N.V. (the 'Executives'), to be submitted for approval by the shareholders of Aegon N.V. (the 'Shareholders') at the Annual General Meeting of Shareholders on May 15, 2020. This Policy replaces the Aegon N.V. Executive Board Remuneration Policy of 2011. Remuneration of all employees of Aegon N.V. and its direct and indirect subsidiaries ('Aegon') and the Executives is governed by the Aegon Group Global Remuneration Framework (the 'Remuneration Framework'). This Policy is aligned with the current version of this Remuneration Framework, which was adopted by the Supervisory Board of Aegon N.V. (the 'Supervisory Board') on December 18, 2019. The Remuneration Committee of the Supervisory Board of Aegon N.V. (the 'Remuneration Committee' ) prepared the changes to this Policy, which were endorsed by the Supervisory Board on March 17, 2020. At the date of approval, the Policy complies with the applicable rules and regulations such as the Dutch Financial Supervision Act, the Dutch Civil Code, the Dutch Corporate Governance Code and the Solvency II Legal Framework.
    [Show full text]
  • Royal DSM Integrated Annual Report 2017 DSM at a Glance Nutrition DSM Nutritional Products and DSM Food Specialties Form Our Nutrition Business
    Royal DSM Integrated Annual Report 2017 DSM at a glance Nutrition DSM Nutritional Products and DSM Food Specialties form our Nutrition business. DSM Nutritional Products provides solutions for animal feed, food and beverages, pharmaceuticals, infant nutrition, dietary supplements and personal care. DSM Food Specialties is a leading global supplier of specialty food enzymes, cultures, bio-preservation, hydrocolloids, savory, and sugar reduction solutions. Materials DSM’s Materials business includes DSM Engineering Plastics, DSM Dyneema, and DSM Resins & Functional Materials. DSM is a global player in specialty plastics for the electrical components and electronics, automotive, fl exible food packaging and consumer goods industries. The materials portfolio also includes Dyneema®, the world’s strongest fi ber™, as well as resins for paints, industrial applications and optical fi ber coatings. Innovation Center DSM Innovation Center accelerates the innovation power and speed of our core businesses. It also has a business development role, focusing on areas outside the current scope of the business groups. The company has three Emerging Business Areas: DSM Biomedical, DSM Bio-based Products & Services and DSM Advanced Solar. Partnerships As part of DSM’s strategic transformation and move away from more commoditized and cyclical areas, we established joint ventures: DSM Sinochem Pharmaceuticals, Patheon and ChemicaInvest. In 2017, DSM divested Patheon for proceeds of about € 1.5 billion. People Planet 21,054 75% 26% 21% Workforce Employee engagement Greenhouse-gas effi ciency Purchased electricity (at year-end 2017, index, up 4% from improvement, cumulative from renewable sources, excluding affi liates) 2016 versus 2008 (on track) up from 8% in 2016 27/73 17% 21% 3% Female/male ratio Female executives, Innovation sales as % Energy effi ciency stable versus 20161 up 2% from 2016 of total sales.
    [Show full text]
  • QIAGEN N.V. Quebec B.V. Thermo Fisher Scientific Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) QIAGEN N.V. (Name of Subject Company (Issuer)) Quebec B.V. (Offeror) a wholly owned subsidiary of Thermo Fisher Scientific Inc. (Ultimate Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issuer, or other person)) Ordinary Shares, €0.01 par value per share (Title of Class of Securities) N72482123 (CUSIP Number of Class of Securities) Michael A. Boxer Senior Vice President and General Counsel Thermo Fisher Scientific Inc. 168 Third Avenue Waltham, Massachusetts 02451 Telephone: (781) 622-1000 (Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons) Copies to: Matthew M. Guest, Esq. Brandon C. Price, Esq. Wachtell, Lipton, Rosen & Katz 51 West 52nd Street New York, New York 10019 Telephone: (212) 403-1000 ​ CALCULATION OF FILING FEES ​ ​ Transaction Valuation(1) Amount of Filing Fee(2) ​ ​ $10,050,234,793 $1,304,521 ​ (1) Calculated solely for purposes of determining the filing fee. The calculation of the transaction valuation assumes the purchase of ordinary shares, par value €0.01 per share (each, a “QIAGEN Share”), of QIAGEN N.V. (“QIAGEN”), at a purchase price of €39.00 per QIAGEN Share in cash, converted into a purchase price of $42.44 per QIAGEN Share using a rate of 1.0883 U.S. dollars per 1.00 Euro, the noon buying rate as of April 17, 2020 published by the Federal Reserve Bank of New York.
    [Show full text]
  • Annual Report and Accounts 2020 and Is an Exact Copy of the Printed Document Provided to Unilever’S Shareholders
    Disclaimer This is a PDF version of the Unilever Annual Report and Accounts 2020 and is an exact copy of the printed document provided to Unilever’s shareholders. Certain sections of the Unilever Annual Report and Accounts 2020 have been audited. These are on pages 112 to 167, and those parts noted as audited within the Directors’ Remuneration Report on pages 90 to 99. The maintenance and integrity of the Unilever website is the responsibility of the Directors; the work carried out by the auditors does not involve consideration of these matters. Accordingly, the auditors accept no responsibility for any changes that may have occurred to the financial statements since they were initially placed on the website. Legislation in the United Kingdom and the Netherlands governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. Except where you are a shareholder, this material is provided for information purposes only and is not, in particular, intended to confer any legal rights on you. This Annual Report and Accounts does not constitute an invitation to invest in Unilever shares. Any decisions you make in reliance on this information are solely your responsibility. The information is given as of the dates specified, is not updated, and any forward-looking statements are made subject to the reservations specified in the cautionary statement on the inside back cover of this PDF. Unilever accepts no responsibility for any information on other websites that may be accessed from this site
    [Show full text]
  • KPN Integrated Annual Report 2018 the Power of Connection
    KPN Integrated Annual Report 2018 The power of connection 1 2 Every day, new technologies offer new opportunities. KPN makes life more free, fun and easy by connecting people 3 IoT First 5G test at full LoRa bandwidth We will soon be able to send a thousand times more data with 5G. This offers huge opportunities. Take the Waalhaven in Rotterdam, where we tested 5G at full bandwidth (100 megahertz) in the Netherlands for the first time. Live images from a drone with a 360-degree camera were linked to an image processing center. In the near future, it will be possible to use this technology to inspect oil refineries, container storage and lots more. 4 5 KPN Integrated Annual Report 2018 Contents KPN at a glance Who we are and what we do Contents 6 The long-term value we create How we safeguard long-term value Financial Statements Appendices KPN at a glance Appendices Introduction by CEO Maximo Ibarra 8 Appendix 1: Alternative performance measures 193 Our main achievements 14 Appendix 2: Overview and connectivity of non-financial Review of the year 20 information 196 Appendix 3: Transparency 200 About this report 200 Who we are and what we do Stakeholder engagement and materiality determination 205 Appendix 4: List of top risks 212 Our purpose and the world around us 24 Appendix 5: Glossary 220 Our strategy and activities 28 Our value creation model 30 Our capitals to operate 34 Digital appendices For an overview of our social and environmental figures The long–term value we create (Appendices 6 and 7) and GRI Index (Appendix 8), please see www.kpn.com/annualreport.
    [Show full text]
  • Unilever Annual Report on Form 20-F 2020 in This Report
    Disclaimer This is a PDF version of the Annual Report on Form 20-F 2020 and is an exact copy of the document filed with the SEC at www.sec.gov. Certain sections of the Annual Report on Form 20-F 2020 have been audited. These are on pages 112 to 167. The maintenance and integrity of the Unilever website is the responsibility of the Directors; the work carried out by the auditors does not involve consideration of these matters. Accordingly, the auditors accept no responsibility for any changes that may have occurred to the financial statements since they were initially placed on the website. Legislation in the United Kingdom and the Netherlands governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. Except where you are a shareholder, this material is provided for information purposes only and is not, in particular, intended to confer any legal rights on you. This Annual Report on Form 20-F does not constitute an invitation to invest in Unilever shares. Any decisions you make in reliance on this information are solely your responsibility. The information is given as of the dates specified, is not updated, and any forward-looking statements are made subject to the reservations specified in the cautionary statement on the inside back cover of the Annual Report on Form 20-F 2020. Unilever accepts no responsibility for any information on other websites that may be accessed from this site by hyperlinks. Purpose-led, future-fit Unilever Annual Report on Form 20-F 2020 In this report
    [Show full text]
  • DSM Annual Report 2016
    Royal DSM Integrated Annual Report 2016 DSM at a glance Nutrition means of DSM’s proprietary processes. The Dyneema® brand enjoys very high recognition in the value chains served. The Nutrition cluster comprises DSM Nutritional Products and DSM Food Specialties. These businesses serve the global DSM Resins & Functional Materials is a global player in industries for animal feed, food and beverages, pharmaceutical, developing, manufacturing and marketing high-quality resins infant nutrition, dietary supplements and personal care. solutions for paints, industrial coatings and fiber-optic coatings. Its continuous innovation means that customers can meet DSM Nutritional Products is one of the world’s leading regulatory needs and respond better to consumer demands for producers of essential nutrients such as vitamins, carotenoids, more sustainable materials. nutritional lipids and other ingredients for the feed, food, pharmaceutical and personal care industries. Among its Innovation Center customers are the world’s largest food and beverage companies. DSM is uniquely positioned, offering a combination DSM Innovation Center serves as an enabler and accelerator of global products and local solutions, with a strong focus on of innovation within DSM, providing support to the clusters. With innovation. DSM Nutritional Products consists of the following its Emerging Business Areas, the Business Incubator and DSM business units: Venturing & Licensing, it also has a general business development role, focusing on areas outside the current scope Animal Nutrition & Health addresses the nutritional additives of the business groups. segment of the global feed ingredients market. DSM's products and premixes include vitamins, feed enzymes, carotenoids, DSM’s Emerging Business Areas provide strong long-term minerals and eubiotics.
    [Show full text]
  • This Report Describes the Imple- Mentation of Our
    REMUNERATION REPORT This report describes the imple- For a full description of the members is directly aimed at strategic mentation of our Remuneration Remuneration Policy for both the Board priorities that will contribute to building of Management and the Supervisory sustainable long-term value creation, with Policy in 2020 for members Board, please visit our website. targets for the return for shareholders and of the Board of Management and the return on invested capital. Following The remuneration for the financial year the separation of Specialty Chemicals, Supervisory Board. 2020, as described in this report, is a one-off long-term incentive to reward subject to an advisory vote at the 2021 bringing value creation at a higher level AGM. Questions raised in the 2020 has been added for the performance We have a clear strategic focus to be - AGM regarding remuneration items were period 2018-2020. come the reference in paints and coatings addressed in the respective meeting, with strong global brands, leading market resulting in 94% votes in favor of the Prior to agreeing on incentives, the positions and a balanced geographic 2019 Remuneration report. Remuneration Committee conducted exposure across all regions. Our strategy scenario analyses of the possible is aimed at long-term value creation. financial outcomes of meeting different 1. REMUNERATION FOR THE performance levels, and how they To realize our strategy and create BOARD OF MANAGEMENT may affect the structure and value the long-term value we aim for, it’s of the Board of Management’s total essential that we can attract and retain The Policy is designed to enable the remuneration.
    [Show full text]